Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia

被引:2
作者
Griffen, Ti'ara L. [1 ]
Hoff, Fieke W. [2 ]
Qiu, Yihua [3 ]
Burger, Jan [3 ]
Wierda, William [3 ]
Kornblau, Steven M. [3 ]
机构
[1] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA
[2] Univ Texas Southwestern Med Ctr, Dept Internal Med, Dallas, TX 75390 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
关键词
CLL; proteomics DDR; 17P DELETION; REPAIR; MUTATIONS; ENDONUCLEASE; RESISTANCE; ERCC1-XPF; CELLS;
D O I
10.3390/ijms24065481
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proteomic DNA Damage Repair (DDR) expression patterns in Chronic Lymphocytic Leukemia were characterized by quantifying and clustering 24 total and phosphorylated DDR proteins. Overall, three protein expression patterns (C1-C3) were identified and were associated as an independent predictor of distinct patient overall survival outcomes. Patients within clusters C1 and C2 had poorer survival outcomes and responses to fludarabine, cyclophosphamide, and rituxan chemotherapy compared to patients within cluster C3. However, DDR protein expression patterns were not prognostic in more modern therapies with BCL2 inhibitors or a BTK/PI3K inhibitor. Individually, nine of the DDR proteins were prognostic for predicting overall survival and/or time to first treatment. When looking for other proteins that may be associated with or influenced by DDR expression patterns, our differential expression analysis found that cell cycle and adhesion proteins were lower in clusters compared to normal CD19 controls. In addition, cluster C3 had a lower expression of MAPK proteins compared to the poor prognostic patient clusters thus implying a potential regulatory connection between adhesion, cell cycle, MAPK, and DDR signaling in CLL. Thus, assessing the proteomic expression of DNA damage proteins in CLL provided novel insights for deciphering influences on patient outcomes and expanded our understanding of the potential complexities and effects of DDR cell signaling.
引用
收藏
页数:13
相关论文
共 50 条
[21]   Increased Expression of Autophagy Protein LC3 in Two Patients With Progressing Chronic Lymphocytic Leukemia [J].
Arroyo, Daniela S. ;
Rodriguez, Cecilia M. ;
Bussi, Claudio ;
Manzone-Rodriguez, Clarisa ;
Sastre, Dario ;
Heller, Viviana ;
Stanganelli, Carmen ;
Slavutsky, Irma ;
Iribarren, Pablo .
FRONTIERS IN ENDOCRINOLOGY, 2020, 11
[22]   The role of TACI expression in chronic lymphocytic leukemia [J].
Bojarska-Junak, Agnieszka ;
Hus, Iwona ;
Sieklucka, Malgorzata ;
Surdacka, Agata ;
Kusz, Maria Luiza ;
Wasik-Szczepanek, Ewa ;
Dmoszynska, Anna ;
Rolinski, Jacek .
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2011, 36 (01) :46-50
[23]   DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy [J].
Tsagiopoulou, Maria ;
Papakonstantinou, Nikos ;
Moysiadis, Theodoros ;
Mansouri, Larry ;
Ljungstrom, Viktor ;
Duran-Ferrer, Marti ;
Malousi, Andigoni ;
Queiros, Ana C. ;
Plevova, Karla ;
Bhoi, Sujata ;
Kollia, Panagoula ;
Oscier, David ;
Anagnostopoulos, Achilles ;
Trentin, Livio ;
Ritgen, Matthias ;
Pospisilova, Sarka ;
Stavroyianni, Niki ;
Ghia, Paolo ;
Martin-Subero, Jose I. ;
Pott, Christiane ;
Rosenquist, Richard ;
Stamatopoulos, Kostas .
CLINICAL EPIGENETICS, 2019, 11 (01)
[24]   Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia [J].
Serpa, Mariana ;
Bendit, Israel ;
Seguro, Fernanda ;
Xavier, Flavia ;
Cavalcante, Marcela ;
Steinbaum, Daniel ;
Nardinelli, Luciana ;
Aldred, Vera Lucia ;
de Paula, Henrique Moura ;
Dorlhiac-Llacer, Pedro Enrique .
ACTA HAEMATOLOGICA, 2010, 124 (02) :105-109
[25]   Protein kinase C isoform expression in chronic lymphocytic leukemia: a potential target for therapy? [J].
Best, O. Giles ;
Tam, Constantine .
LEUKEMIA & LYMPHOMA, 2013, 54 (10) :2098-2099
[26]   Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia [J].
Kazi, Julhash U. ;
Kabir, Nuzhat N. ;
Ronnstrand, Lars .
MEDICAL ONCOLOGY, 2013, 30 (04)
[27]   BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia [J].
Chong, Stephen Jun Fei ;
Lu, Junyan ;
Valentin, Rebecca ;
Lehmberg, Timothy Z. ;
Eu, Jie Qing ;
Wang, Jing ;
Zhu, Fen ;
Kong, Li Ren ;
Fernandes, Stacey M. ;
Zhang, Jeremy ;
Herbaux, Charles ;
Goh, Boon Cher ;
Brown, Jennifer R. ;
Niemann, Carsten U. ;
Huber, Wolfgang ;
Zenz, Thorsten ;
Davids, Matthew S. .
MOLECULAR CANCER, 2025, 24 (01)
[28]   Patterns of use of biological and genetic markers for chronic lymphocytic leukemia and acute myeloid leukemia in Puerto Rico [J].
Ortiz-Ortiz, Karen J. J. ;
Torres-Cintron, Carlos R. R. ;
Ramos, Tonatiuh Suarez ;
Castaneda-Avila, Maira A. A. ;
Cotto Santana, Luis A. A. ;
Tortolero-Luna, Guillermo .
CANCER MEDICINE, 2023, 12 (06) :6889-6901
[29]   Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia [J].
Del Giudice, Ilaria ;
Della Starza, Irene ;
De Falco, Filomena ;
Gaidano, Gianluca ;
Sportoletti, Paolo .
CANCERS, 2024, 16 (11)
[30]   AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations [J].
Leuenberger, Mona ;
Frigerio, Simona ;
Wild, Peter J. ;
Noetzli, Franziska ;
Korol, Dimitri ;
Zimmermann, Dieter R. ;
Gengler, Carole ;
Probst-Hensch, Nicole M. ;
Moch, Holger ;
Tinguely, Marianne .
MODERN PATHOLOGY, 2010, 23 (02) :177-186